GeneWeave Attracts $12 Million to Provide Same-Shift Sample-In/Susceptibility-Out Diagnostic Solutions for Multi-Drug-Resistant Organisms
July 2, 2014

LOS GATOS, Calif July 02, 2014

GeneWeave Biosciences, Inc., a clinical diagnostics company addressing multi-drug-resistant organisms (MDRO), today announced the completion of its $12 million Series B financing. The financing was led by Decheng Capital and included full participation of the existing investors Claremont Creek Ventures and XSeed Capital.

Proceeds from the financing will support clinical studies and commercialization of the company’s sample-in/susceptibility-out platform technology. “We are very excited to have the continued support of our investors as we develop diagnostic solutions to make patient care safer and more affordable,” said Steve Tablak, GeneWeave’s Chief Executive Officer. “With the rise of multi-drug resistant bacteria as a truly global health threat, the need for solutions that rapidly identify pathogens and determine their antibiotic resistance or susceptibility is greater than ever and GeneWeave has developed a transformative platform technology that addresses this problem.”

The emergence and spread of bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA) and Carbapenem-resistant Enterobacteriaceae (CRE) that are resistant to currently available antibiotics is a worldwide threat recently highlighted in the World Health Organization’s (WHO) report, Antimicrobial Resistance Global Report on Surveillance 2014. The report estimates that antimicrobial resistance results in an additional 8 million hospital days in the U.S. every year. The Centers for Disease Control and Prevention (CDC) estimates that more than 2 million people acquire a serious antibiotic-resistant bacterial infection every year and at least 23,000 people die as a result. Developing new diagnostics for resistant bacteria is one of four core actions recommended by the CDC to fight these infections and stay ahead of emerging resistant organisms.

About GeneWeave
GeneWeave Biosciences, Inc., based in Los Gatos, Calif., is a privately-held in vitro diagnostics company that is advancing clinical microbiology with diagnostic solutions that will enable hospitals and physicians around the world to prevent drug-resistant infections, improve antibiotic stewardship and quickly determine the optimal antibiotic therapy for critical bacterial infections. The company’s innovative and proprietary Smarticles? technology harnesses the power of biology to enable homogeneous assays that rapidly measure bacterial drug resistance without the need for enrichment, culture, or sample preparation.

About Decheng Capital
Decheng Capital is a leading venture capital firm that provides capital to early and growth stage life science companies in China and the U.S. Their team of investment professionals has complementary expertise, a long history of working together and a shared dedication to building highly successful companies that span the full spectrum of the life sciences industry. Their domain knowledge, access to innovative technologies and ability to bring proven Western products to China makes them the preferred partner for entrepreneurs, domestic and multinational companies, government agencies and investors. For more information visit

About Claremont Creek Ventures
Claremont Creek Ventures (CCV) is a seed and early stage venture firm. CCV invests in companies that serve essential, broad-impact industries with innovative digital solutions that increase efficiency or create entirely new high-growth, high-margin businesses. As part of CCV's investment strategy, the firm practices "life cycle venturing": establishing in-depth, active relationships with entrepreneurs alongside or even ahead of early-stage funding events. Claremont Creek Ventures has invested in over 40 companies including Natera, AssureX Health, GeneWeave Biosciences, DNAnexus, and Numedii and manages more than $300 million across two funds. Visit

About XSeed Capital
Founded in 2006 as one of the pioneers of the new venture industry, XSeed Capital is an early stage investment firm that works with entrepreneurs who are setting the world on fire by building category-leading, high growth companies. XSeed makes initial investments at the seed stage and continues to support its portfolio companies with time, effort and follow-on capital through multiple investment rounds. XSeed primarily invests in companies in the software, computer science and broader IT areas. Leading companies include: StackStorm, CirroSecure, Trifacta, Zooz, AtScale, Chatous, Lex Machina, Biota, DropThought, SIPX, Pixlee, and GeneWeave Biosciences. For more information, visit or follow XSeed on Twitter (@xseedcapital).

Copyright ? 2011 Decheng Capital LLC. All Rights Reserved.
浙江20选5预测推荐 重庆幸运农场胆拖表 快乐十分开奖结查询广东 捕鸟达人单机版 加工扑克麻将透视眼镜 福彩快3开奖号码 赛马会全年资料 北京赛车pk10直播网站 浙江福彩双色球开奖 北京pK10开奖历史记录 股票交易流程 新世界棋牌icon 水果拉霸游戏压线押注诀窍 如何查看彩票中奖结果 吉利心水论坛全国 甘肃11选5任5拖胆玩法 体彩20选5第18207期